Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Purdue Pharma L.P. has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 6 distinct examiners and 5 distinct art units, showing separate examiner assignments with some concentration among technical groups.
BAGNAL, CINDY LILIANA is the busiest examiner, with 1 pending matter. Because the examiner count matches the action count, counsel cannot rely on repeated examiner treatment to guide responses. The lower art-unit count supports reviewing at least one group for shared technical or procedural patterns.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (67%) |
| §112 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAGNAL, CINDY LILIANA | 1 | — | — |
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| KENYON, JOHN S | 1 | 79.8% | +18.1% |
| YOUNG, MICAH PAUL | 1 | 55.1% | +30.0% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918012 | COMPOSITIONS AND METHODS FOR EMERGENCY RESCUE | WAX, ROBERT A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17910199 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | YOUNG, MICAH PAUL | 6d |
| 18746814 | PHARMACEUTICAL DOSAGE FORMS | TCHERKASSKAYA, OLGA V | — |
| 18389356 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | KENYON, JOHN S | — |
| 17059761 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1621 | 1 |
| 1625 | 1 |
| 1618 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18878591 | METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME | BAGNAL, CINDY LILIANA | 1621 | §103 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18746814 | PHARMACEUTICAL DOSAGE FORMS | TCHERKASSKAYA, OLGA V | 1615 | §112Other | Final Rejection | — | Pending | Jun 18, 2024 |
| 18389356 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | KENYON, JOHN S | 1625 | §102DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 17910199 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | YOUNG, MICAH PAUL | 1618 | §103 | Final Rejection | 6d | Pending | Feb 22, 2023 |
| 17918012 | COMPOSITIONS AND METHODS FOR EMERGENCY RESCUE | WAX, ROBERT A | 1615 | §103 | Non-Final OA | — | Pending | Oct 10, 2022 |
| 17059761 | COMPOSITIONS AND METHODS FOR OPIOID OVERDOSE RESCUE | COPPINS, JANET L | 1628 | §103 | Final Rejection | — | Pending | Nov 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPurdue Pharma L.P. has 6 pending office actions as of November 2026, spread across 5 art units and 6 examiners.
Cindy Liliana Bagnal has the most, with 1 of Purdue Pharma L.P.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.